Steve Yang to join AstraZeneca as head of Asia and emerging markets R&D
This article was originally published in Scrip
Executive Summary
Dr Steve Yang has been named vice-president and head of R&D for Asia and emerging markets at AstraZeneca, effective 6 January. Dr Yang, previously a vice-president and head of Asia R&D for Pfizer, will continue to be based in Shanghai and report to Martin Mackay, AstraZeneca's R&D president. Part of his responsibilities at Pfizer included building up Asia-Pacific partnerships with academia, biotech ventures and contract research organisations to tap into regional research expertise (scripintelligence.com, 6 July 2010). Dr Yang is also a co-founder of the BayHelix group, a network of Chinese life science business leaders.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.